Kadimastem - Stem Cell to Cure Diseases

News & Events > Press Releases

Success for Kadimastem in Rights Offering;

Feb. 28, 2017
Raised NIS 7.2M 71% of the rights offered were exercised

Kadimastem Announces Strategic Collaboration with Korean Biotech Company Corestem, Including a $7M Investment in Kadimastem

Dec. 7, 2016
Corestem is the only company in the world with a cell therapy treatment for ALS which has been approved for marketing by a regulatory authority. Corestem believes in Kadimastem's technologies in the ALS and diabetes fields, and the agreement will assist in expediting Kadimastem's entry into the market

Stakeholders' Support for Kadimastem Continues: Investment of NIS 2.5M by Way of Convertible Loan

Nov. 9, 2016
If an investment agreement of $ 2M or more will be signed with a foreign company or investor, the loan will be converted in a rights offering under identical terms

Towards the Company's First Clinical Trial;

Nov. 2, 2016
Kadimastem Signs Letter of Intent with Hadassah Medical Center for Performance of the Clinical Trial in ALS

Progressing Towards Clinical Trials: Kadimastem Proves Efficacy of Its Unique ALS Treatment in Pre-Clinical Trials

Aug. 18, 2015
The company will approach the FDA to continue the approval process for its clinical trials Yossi Ben-Yossef, Kadimastem’s CEO: “The excellent results of the trial pave the way for our clinical trials, and allow the company to launch the product’s manufacturing according to GMP standards

Chief Scientist Increases Budget to Advance Kadimastem's Cell Therapy for ALS

Jul. 20, 2014
The total budgets for 2014 will now stand at about NIS 10 million.

Kadimastem Receives Approval for U.S. Patent

Jun. 2, 2014
Kadimastem Receives Approval for U.S. Patent Protecting a Key Technology of the Company

Kadimastem Reinforces its Status as a World Leader in the Field of Stem Cells

May. 1, 2014
Professor Itzkowitz-Eldor will join Kadimastem’s Scientific Advisory Board

Leading pharma entrepreneur Avi Meizler believes in Kadimastem!

Mar. 19, 2014
Leading Pharma Entrepreneur Invests around 1.7 million shekels in the Company

Kadimastem announces its intention to reduce the exercise price for warrants (Series 1)

Feb. 3, 2014
Kadimastem announces its intention to reduce the exercise price for warrants (Series 1)

Press Releases Archive